Navigation Links
Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2013 Sales And EPS Of $675 Million And $1.01, Respectively, Both Record Quarterly Highs. Reaffirms Full Year 2013 Diluted Adjusted EPS Outlook Of $4.10 To $4.20.
Date:4/25/2013

es in worldwide tax rates or tax benefits from domestic and international operations, including the matters described in Note 11 – Income Taxes, to the Company's consolidated financial statements included in Item 8, Part II of the Company's Annual Report on Form 10-K for the year ended December 31, 2012 (the "10-K"), (9) exposure to litigation including product liability claims, (10) the ability to maintain adequate quality standards, (11) reliance on third party package delivery services, (12) an unanticipated increase in interest rates, (13) other changes in the business environment in which the Company operates, (14) acquisitions or divestitures of businesses, and (15) the outcome of the outstanding matters described in Note 12 – Contingent Liabilities and Commitments, to the Company's consolidated financial statements included in Item 8, Part II of the 10-K.  A further discussion of the Company's risk factors can be found in Item 1A of Part I of the 10-K.  The Company does not undertake any obligation to update these forward-looking statements.

About Sigma-Aldrich:  Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical and organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing.  Sigma-Aldrich customers include more than one million scientists and technologists in life science companies, university and government institutions, hospitals and industry.  The Company operates in 37 countries and has approximately 9,000 employees whose objective is to provide excellent service worldwide.  Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science, High Technology and Service.  For mo
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Sigma-Aldrich Announces Q1 2013 Earnings Conference Call
2. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
3. Sigma-Aldrich Reports Record Full Year 2012 Results. Reports Q4 2012 Diluted EPS Of $0.96. Q4 2012 Sales Increased 7%. Full Year 2012 Adjusted Diluted EPS Was $3.85. Expects Full Year 2013 Adjusted Diluted EPS To Increase To $4.10 - $4.20.
4. Sigma-Aldrich Aligns Into Three New Market-Focused Business Units
5. Sigma-Aldrich (NASDAQ: SIAL) Declares $0.20 Quarterly Dividend
6. Sigma-Aldrich Enhances Customer Focus in China - Unveils Dynamic New Website and Expands Product Offering Through Vetec Brand
7. Sigma-Aldrich Corporation To Present At Upcoming Investor Conferences
8. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
10. Morgan & Morgan Announces Investigation of MAP Pharmaceuticals (NASDAQ: MAPP)
11. SHAREHOLDER ALERT: Morgan & Morgan announces an investigation of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and whether senior management and the board of directors violated fiduciary duties owed to Vertex shareholders.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of its previously announced underwritten public offering of ... public offering price of $11.25 per share. The ... 1,000,000 shares issued upon the exercise in full ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 /PRNewswire/ ... Co., Ltd. (Headquarters: Tokyo , President ... Therapeutics, Inc. (Headquarters: San Diego, California ... "NASDAQ: HALO") have signed a clinical collaboration agreement to ... "eribulin") in combination with Halozyme,s investigational drug PEGPH20 (PEGylated ...
(Date:7/31/2015)... According to a new market ... Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air ... & Forecast to 2019", published by MarketsandMarkets, the global ... 2014 and is estimated to grow to $1,425.7 Million ... 2014 to 2019. Browse 41 market ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) today announced that it ... FDA Panel meeting on Monday, May 10, 2010 at ... . Don Bailey , President and Chief Executive Officer; Steve ... , Chief Science Officer; and Dr. Jason Zielonka , Senior Vice President ...
... , May 3 Watson Pharmaceuticals, Inc. (NYSE: WPI ... Watson,s president and chief executive officer, will provide an overview and update of ... Tuesday, May 11, 2010 at 1:40pm Eastern Daylight Time ... , , ...
Cached Medicine Technology:Questcor to Discuss Results From FDA Panel Meeting 2Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference 2
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... in Boston, when Major League Baseball and the Boston Red Sox honor Ice Bucket ... taking the challenge. MLB is donating $100,000 to further collaborative efforts among the ALS ...
(Date:7/31/2015)... ... July 31, 2015 , ... Successful Import/Export Programs:, Former FDA ... , Having FDA-regulated products held at ports costs time, money and the competitive ... or even destruction — of products, an FDA insider shows manufacturers how to ...
(Date:7/31/2015)... ... July 31, 2015 , ... Burnaby sports physiotherapy clinic, Absolute ... understanding and treatment of ankle sprains. A common sports injury, ankle sprains are ... dangerous if the condition augments and causes more disruption. Absolute PhysioCare’s blog discusses ...
(Date:7/31/2015)... ... July 31, 2015 , ... everMaya ... their latest designer handbag line will be named for Madeline Stuart, an 18-year-old ... the first globally recognized model with Down syndrome, gracing the front pages of ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... as a contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management ... help long-term and post-acute care providers understand the benefits of using medication ...
Breaking Medicine News(10 mins):Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3
... they become pregnant are at higher risk of having children ... reading tests taken between ages 5 to 7 years - ... suggests. In this large observational study, prepregnancy obesity was ... and a two-point reduction in math scores on a commonly ...
... , TUESDAY, May 8 (HealthDay News) -- The ... bulge has been slow, but certain strategies could speed ... Institute of Medicine (IOM) on Tuesday outlined five recommendations ... recommendations come not a moment too soon: On Monday, ...
... cells have the ability to recycle unwanted or damaged proteins ... have ramped up the system, called autophagy, and rely on ... other treatments. Now, researchers at the Perelman School of Medicine; ... Sciences, at the University of Pennsylvania, have developed a potent ...
... HealthDay Reporter , MONDAY, May 7 (HealthDay News) -- Among ... earlier than thought, a new large survey analysis reveals. ... the last year of high school or college to take ... opioid painkillers, it,ll be a case of too little, too ...
... May 8, 2012 Gene Signal, a company focused ... today announced that positive data from a study of ... of choroidal neovascularization has been presented at the 2012 ... of aganirsen was found to inhibit neovascular growth and ...
... researchers have discovered that a drug already prescribed to ... important use: treating one of the world,s leading causes ... experiments, the scientists found that metformin, which is commonly ... diabetes, also substantially reduced the effects of uveitis, an ...
Cached Medicine News:Health News:Study shows link between pre-pregnancy obesity and lower test scores 2Health News:Study shows link between pre-pregnancy obesity and lower test scores 3Health News:U.S. Report Outlines Strategies to Prevent Obesity 2Health News:Block its recycling system, and cancer kicks the can, according to new Penn study 2Health News:Kids Most Likely to Start Abusing Painkillers at 16: Study 2Health News:Kids Most Likely to Start Abusing Painkillers at 16: Study 3Health News:Gene Signal presents data at ARVO 2012 showing topical aganirsen is active in retinal disease 2Health News:Diabetes drug could treat leading cause of blindness 2
The Multiple Perfusion set provides simultaneous perfusion of the aortic root and up to three or more vein grafts. The set features an inlet port with female luer and clamp attached to an adapter whi...
The Aortic Root Cannulae With Vent Line are flanged, with radiopaque tips; two side holes in tip....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
... Medtronic Select CAP® cannulae provides a ... pressure readings. An innovative combination of ... monitoring line, the Select CAP® can ... central arterial pressure readings on which ...
Medicine Products: